Abstract: Computer-assisted methods for assisting in anomaly identification relating to a dysmorphology analysis comprise retrieving and/or generating a sequence of progressively changing images that depict morphing of at least a subject's first physical feature, between at least a first state representing an identification of a first anomaly relating to a dysmorphology and a second state representing lack of the identification of the first anomaly. The number of images in the sequence is selected to provide a substantially continuous transition between the first and second states. The retrieved and/or generated images are displayed on a display of a processing device, and a user interface on the processing device is provided for a user to make an image selection, which can then be used to determine identification or lack of identification of the anomaly.

Abstract: A testing apparatus for dynamic characterization of a sample of a material under test. A terahertz (THz) time-domain spectroscopy system is configured and arranged to generate and detect terahertz waves to interrogate the sample. A shock wave loading system is configured and arranged to produce a shock wave in the sample concurrently with said THz spectroscopy device interrogating the sample. The sample undergoes changes in an index of refraction in response to the produced ultrafast shock wave in the sample that are detected by the terahertz spectroscopy system.

Abstract: In alternative embodiments, provided are compositions and methods for making a chimeric polypeptide comprising an S-layer polypeptide and a heterologous polypeptide or peptide. In alternative embodiments, the compositions and methods comprise recombinantly engineering a methylotrophic or methanotrophic bacteria to recombinantly express a chimeric polypeptide comprising an S-layer polypeptide and a heterologous polypeptide or peptide. Also provided are compositions and methods for displaying or immobilizing proteins on a methanotrophic S-layer. In alternative embodiments, provided are compositions and methods comprising recombinant methylotrophic or methanotrophic bacteria comprising assembled or self-assembled recombinant or isolated chimeric S-layer polypeptides. In alternative embodiments, provided are compositions and methods using recombinant methylotrophic or methanotrophic bacteria, optionally a Methylomicrobium alcaliphilum, optionally a M. alcaliphilum sp.

Abstract: Apparatus for near-field wireless energy transfer. A first layer provides or comprises a piezoelectric phase or a material with or adapted for electromechanical coupling; and a second layer provides or comprises a magnetostrictive phase or a material with or adapted for a magnetomechanical coupling. The second layer is mechanically and/or chemically coupled to the first layer to provide a composite structure.

Abstract: A method for designing a channel estimation and data detection networks is provided herein. The problem of channel estimation for linear systems has effectively been solved—not the case for non-linear systems. A deep learning framework for channel estimation, data detection, and pilot signal design is described to address the nonlinearity in such systems.

Abstract: The invention provides a series of conformationally stable kinase inhibitors, and methods of using the kinase inhibitors. The effect of atropisomerism on kinase selectivity was assessed, finding improved selectivity compared to rapidly interconverting parent compounds.

Abstract: Provided are compositions and methods for treating, ameliorating and preventing various infections, disorders and conditions in mammals, including genetically-predisposed and chronic disorders, where a microbial or bacterial flora is at least one causative or symptom-producing factor, where exemplary compositions are products of manufacture, a food, a drink, a nutraceutical, a dietary supplement, a formulation, a pharmaceutical or a pharmaceutical preparation comprising at least one or several of a plurality of isolated, or substantially purified bacteriophages or prophages, or bacteriophage subunits, a milk, a milk product, milk lipid, milk fat globule (MFG) macromolecule, a milk mucin, a milk glycolipid, a milk free glycan, a milk mucin-like glycoprotein, a milk protein, a milk sugar or lactose, a milk fat or butterfat, a milk vitamin.

Abstract: In alternative embodiments, provided are compositions comprising chemically or structurally modified bacteriophages of the genus Caudovirales having an exterior or outer surface comprising at least one heterologous carbohydrate binding domain (CBD) comprising a lectin or a plurality of additional homologous CBDs, or more CBDs than found on a comparable wild type (WT) bacteriophage.

Abstract: A system and method for detecting, amplifying, and sorting non-transitory signals stemming from cellular activity of tissue in an extracellular medium is presented herein. Weak signals are difficult to detect, especially when they originate far from the measuring electrode. The invention takes advantage of stochastic resonance, i.e. adding noise to signals to amplify them and make them more detectable, to improve signal detection from a single electrode.

Abstract: The invention provides a series of conformationally stable and selective kinase inhibitors, and methods of using the kinase inhibitors. The effect of atropisomerism on kinase selectivity was assessed, finding improved selectivity compared to rapidly interconverting parent compounds. The compounds herein are atropisomers having increased kinase selectivity, and are for use in treating conditions that benefit from selective kinase inhibition.

Abstract: Disclosed and described herein are smart, high-speed UV communication protocols, inspired by the biological principles. The disclosed and described protocols use a ‘pipe’ routing topology to deliver large amount of data among the UVs equipped with multi-beam antennas. The disclosed and described embodiments include bio-inspired pipe routing and adaptive batch coding (ABC) based congestion control. In regard to bio-inspired pipe routing, a human's brain uses highly cooperative neuro cells to memorize everything. Inspired by neuro networks, a pipe architecture with high-throughput node-to-node data delivery is disclosed and described herein. The pipe routing uses multi-beam antennas to achieve parallel data transmission. In regard to ABC based congestion control, a new network coding called ABC is disclosed, which can minimize traffic congestion occurrences in the above pipe routing. The disclosed and described transport layer protocol includes both end-to-end reliability and congestion control.

Abstract: Provided are compositions, e.g., multiplexed platforms or systems, to screen for molecules, e.g., small molecule active agents such as drugs, that inhibit enzymes such as proteases. Provided are cell-based or multiplexed platforms for monitoring or assay the activity of a protease. Provided are cell-based assays and multiplexed systems for the monitoring of enzyme, activity such as proteolytic cleavage on the cell surface, where optionally the protein, e.g., an enzyme, can be naturally expressed on the cell surface or engineered to be expressed on the cell's surface. Provided are cells and stable cell lines expressing an “assay construct” and an enzyme of interest, where optionally one cell or cell line expresses both the “assay construct” and the enzyme, or two different cells or independent cell lines are used and mixed in the assay, where one expresses the “assay construct” with the enzyme substrate and the second expressing the enzyme.

Abstract: A MAC design for Ku-band mobile wireless mesh network with multi-beam smart antennas is disclosed. This MAC includes an overlay control that separates the collision domain. It also has lower layer CSMA-like scheme. The disclosed design includes an enhanced PCF and an enhanced DCF for two purposes: (1) exploiting multi-beam concurrent communication capability (2) supporting QoS and mission-based communications. An efficient time synchronization scheme is also disclosed to ensure all beams can concurrently send data to the star node. Finally, ARMA or HMM based prediction schemes are disclosed to predict future traffic profile in each beam. This helps the star node to better prepare the queue content and schedule information.

Abstract: Disclosed herein are systems and methods directed to routing in the wireless mesh network (WMN) with multi-beam directional antennas (MBDAs). The disclosed systems and methods describe Ripple-Diamond-Chain (RDC) shaped routing, systematic link quality modeling and artificial intelligence (AI) augmented path link selection. In simulations, real-time video as well as other types of traffic types are used to validate the high-throughput, quality of service (QoS)-differentiated, multi-beam routing efficiency of the disclosed systems and methods, as well as the intelligent path determination in dynamic WMN environments.

Abstract: In alternative embodiments, provided are chimeric cells, which in alternative embodiments are the so-called “cardiochimeras”, and methods for making and using them. In alternative embodiments, exemplary chimeric cells as provided herein comprise a cardiac stem cell of cardiac origin or a cardiac progenitor cell fused to either a mesenchymal progenitor cell or mesenchymal stem cell, an endothelial progenitor cell or endothelial stem cell, or a cardiac stem cell or a cardiac progenitor cell. In alternative embodiments, the chimeric cells as provided herein comprise an endothelial progenitor cell, which may or may not be of cardiac origin, fused to either a mesenchymal progenitor cell or mesenchymal stem cell, an endothelial progenitor cell or endothelial stem cell, or a cardiac stem cell or a cardiac progenitor cell. In alternative embodiments, methods for making chimeric cells as provided herein further comprise selecting a cell fusion product comprising a viable chimera of the fused cells.

Abstract: A cross-layer encoder for providing UEP encoding of video data configured to provide UEP encoding of video data at an application layer of a transmission channel by receiving video packets having first and second priority levels, applying first and second coding schemes to video packets having first and second priority levels, respectively, and transmitting video frames having first and second priority levels. The cross-layer encoder can be configured to provide UEP encoding of video data at a physical layer of the transmission channel by receiving encoded video frames having first and second priority levels, applying third and fourth coding schemes to video frames having first and second priority levels, respectively, and transmitting cross-layer encoded video frames having first and second priority levels. The first through fourth coding schemes can generate different percentages of the total coding overhead based on first and second priority levels, respectively.

Abstract: The invention is directed to compositions, e.g., cell-based and multiplexed platforms, to screen for small molecule drugs that inhibit enzymes such as proteases, e.g., viral proteases, e.g., HIV proteases; and methods for making and using these compositions. The invention provides compositions and methods for identifying compositions, e.g., drug molecules, that can inhibit proteases, e.g., viral proteases such as HIV proteases. In alternative embodiments, the invention provides cell-based platforms or assays to screen for compositions, e.g., small molecules or drugs, that inhibit or modify the activity of enzymes such as calcium-dependent protein convertases involved in HIV envelope protein processing, including cleavage of the HIV gp160 envelope precursor, resulting in gp120 and gp41 envelope products. In one embodiment, the invention provides a cell-based or multiplexed platform for monitoring the activity of enzymes, e.g., proteases such as viral proteases.

Abstract: The invention is directed to compositions, e.g., cell-based and multiplexed platforms, to screen for small molecule drugs that inhibit enzymes such as proteases, e.g., viral proteases, e.g., HIV proteases; and methods for making and using these compositions. The invention provides compositions and methods for identifying compositions, e.g., drug molecules, that can inhibit proteases, e.g., viral proteases such as HIV proteases. In alternative embodiments, the invention provides cell-based platforms or assays to screen for compositions, e.g., small molecules or drugs, that inhibit or modify the activity of enzymes such as calcium-dependent protein convertases involved in HIV envelope protein processing, including cleavage of the HIV gp160 envelope precursor, resulting in gp120 and gp41 envelope products. In one embodiment, the invention provides a cell-based or multiplexed platform for monitoring the activity of enzymes, e.g., proteases such as viral proteases.

Abstract: The invention is directed to compositions to screen for compounds, e.g., small molecules or drugs, that can modulate or inhibit enzymes, e.g., proteases, such as viral proteases, e.g., HIV proteases; and methods for making and using these compositions. In alternative embodiment, the invention provides compositions and methods for identifying compositions, e.g., drug molecules that can modulate or inhibit enzymes, e.g., proteases, proteinases or peptidases or the like, e.g., HIV proteases. In alternative embodiments, the invention provides cell-based assays to screen for compositions, e.g., small molecules or drugs, that modulate or inhibit or modify the activity of enzymes such as proteases, proteinases or peptidases or the like, such as calcium-dependent protein convertases involved in HIV envelop protein processing, including cleavage of the HIV gp160 envelope precursor, resulting in gp120 and gp41 envelope products.

Abstract: The invention provides compositions (e.g., pharmaceutical compositions) comprising nucleic acids encoding the serine/threonine kinase PIM-1, and methods for making and using them; including methods for inducing cellular proliferation, and protecting cardiac cells from hypoxia and cellular apoptosis. The invention provides compositions (e.g., pharmaceutical compositions) comprising nucleic acids encoding PIM-1, and methods for enhancing the regenerative potential of stem cells in the heart.